Ucb SA
XBRU:UCB

Watchlist Manager
Ucb SA Logo
Ucb SA
XBRU:UCB
Watchlist
Price: 178 EUR -2.57% Market Closed
Market Cap: 33.8B EUR
Have any thoughts about
Ucb SA?
Write Note

Relative Value

The Relative Value of one UCB stock under the Base Case scenario is 148.24 EUR. Compared to the current market price of 178 EUR, Ucb SA is Overvalued by 17%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

UCB Relative Value
Base Case
148.24 EUR
Overvaluation 17%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
1
vs Industry
26
Median 3Y
3
Median 5Y
3
Industry
2.6
Forward
5.8
vs History
1
vs Industry
4
Median 3Y
37
Median 5Y
21.1
Industry
23
Forward
41.6
vs History
1
vs Industry
12
Median 3Y
14.3
Median 5Y
14.5
Industry
17.8
vs History
4
vs Industry
10
Median 3Y
32.5
Median 5Y
28.5
Industry
25.4
vs History
1
vs Industry
26
Median 3Y
1.8
Median 5Y
2.1
Industry
2.2
vs History
1
vs Industry
23
Median 3Y
3.3
Median 5Y
3.2
Industry
2.8
Forward
6.3
vs History
1
vs Industry
26
Median 3Y
4.6
Median 5Y
4.4
Industry
5.4
vs History
6
vs Industry
15
Median 3Y
13.4
Median 5Y
12.7
Industry
13.7
Forward
25
vs History
1
vs Industry
7
Median 3Y
24.9
Median 5Y
16.5
Industry
17.2
Forward
45.9
vs History
1
vs Industry
11
Median 3Y
15.8
Median 5Y
15.8
Industry
16.5
vs History
1
vs Industry
7
Median 3Y
24.9
Median 5Y
24
Industry
19.3
vs History
1
vs Industry
33
Median 3Y
1.5
Median 5Y
1.7
Industry
2

Multiples Across Competitors

UCB Competitors Multiples
Ucb SA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
BE
Ucb SA
XBRU:UCB
33.8B EUR 6.2 140.7 30.3 71.7
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
746.8B USD 18.3 89.2 48 53.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
3.3T DKK 12.3 35 24.4 27.8
US
Johnson & Johnson
NYSE:JNJ
365.6B USD 4.2 24.9 12 15.7
US
Merck & Co Inc
NYSE:MRK
249.1B USD 3.9 20.5 10.4 12.4
CH
Roche Holding AG
SIX:ROG
208.6B CHF 3.6 18.1 10.2 12.1
CH
Novartis AG
SIX:NOVN
181.4B CHF 4.2 12.6 10 14.8
UK
AstraZeneca PLC
LSE:AZN
159.6B GBP 4.1 31.4 169.3 253.8
IE
Endo International PLC
LSE:0Y5F
146B USD 63 -49.9 234.4 587.7
P/E Multiple
Earnings Growth
BE
Ucb SA
XBRU:UCB
Average P/E: 46.6
140.7
399%
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
89.2
451%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
DK
Novo Nordisk A/S
CSE:NOVO B
35
86%
US
Johnson & Johnson
NYSE:JNJ
24.9
-22%
US
Merck & Co Inc
NYSE:MRK
20.5
7 336%
CH
Roche Holding AG
SIX:ROG
18.1
32%
CH
Novartis AG
SIX:NOVN
12.6
21%
UK
AstraZeneca PLC
LSE:AZN
31.4
177%
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -49.9 N/A

See Also

Discover More
Back to Top